Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q2 2023 call → NOWe need to determine if the company is currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event at the end. The transcript is about Nanobiotix, a biotech developing NBTXR3. They have ongoing clinical trials, partnerships, etc. The question asks if management describes the company as currently paying for something not yet earning, with the wait being the main current work, and the far side being a specific near-dated event. Let's analyze the transcript. Management discusses their clinical programs, upcoming data readouts, and the Janssen partnership. They mention costs: R&D expenses, SG&A, etc. But are they describing a situation where they are paying for something that hasn't arrived yet, and the end is a specific event? For example, they are running clinical trials, which are costs, and they expect data readouts in the coming months. But is that a "waiting period" where they are paying for something not yet earning? In biotech, clinical trials are investments, but the company is not earning revenue from them yet. However, the question is more specific: "the company is presently carrying real, ongoing cash or earnings cost for something whose benefit has not arrived yet, AND that the end of that waiting period is a specific, near-dated event the company can already see and is already working toward." Management mentions upcoming data presentations: "we expect to present safety and efficacy data at a medical meeting in the coming weeks" for Study 102, and "initial Phase 1 dose escalation data in pancreatic cancer" in coming weeks, and "interim results for our NANORAY-312 Phase 3 trial in head and neck cancer" in second half of next year. These are events that will provide data, but are they the "earning" side? The company is not earning revenue from these data; they are clinical milestones. The question might be about a business that is paying for a facility or a product launch, but here it's about clinical development. The company is spending on R&D, but that is its normal business. The "benefit" of a clinical trial is the data, but the company is not earning money from that directly. The question says "something not yet earning" - meaning the company is paying for something that will generate revenue or profit later. In biotech, the product is not yet approved, so all costs are investments.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.